Enhancer of zeste homolog 2: A potential target for tumor therapy

被引：31

作者：

Xiao, Yongtao ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China

来源：

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2011年 / 43卷 / 04期

关键词：

Enhancer of zeste homolog 2; H3K27; Methylation; Phosphorylation; Cancer therapy; GROUP PROTEIN EZH2; MALIGNANT MYELOID DISORDERS; H3; LYSINE-27; METHYLATION; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; CRITICAL REGION; GENE; EXPRESSION; MECHANISMS; BLADDER;

D O I：

10.1016/j.biocel.2011.01.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Enhancer of zeste homolog 2 (EZH2) is a subunit of the Polycomb-Repressive Complex 2 (PRC2), which catalyses the trimethylation of histone H3 on Lys 27 (H3K27) and involves in genes repression. EZH2 is amplified and overexpressed in a variety of cancers, including prostate and breast cancer. Overexpression of EZH2 has been associated with the invasion and progression of malignant cancers, especially with the progression of prostate cancer. Here, we review the structure and biological function of EZH2, especially focused on its activities in the tumorigenesis. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：474 / 477

页数：4

共 50 条

[21] Enhancer of zeste homolog 2 depletion arrests the proliferation of hepatoblastoma cells
Wang, Yue
Xiao, Yongtao
Chen, Kai
Chen, Sheng
Zhang, Min
Wu, Zhixiang
Wu, Yeming
MOLECULAR MEDICINE REPORTS, 2016, 13 (03) : 2724 - 2728
[22] Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer
Warrick, Joshua I.
Raman, Jay D.
Kaag, Matthew
Bruggeman, Trey
Cates, Justin
Clark, Peter
DeGraff, David J.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 258.e1 - 258.e6
[23] Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment
Marchesi, Irene
Bagella, Luigi
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2016, 7 (02): : 135 - 148
[24] Assessment of the Therapeutic Potential of Enhancer of Zeste Homolog 2 Inhibition in a Murine Model of Bronchiolitis Obliterans Syndrome
Matsudo, Kyoto
Takamori, Shinkichi
Takenaka, Tomoyoshi
Shimokawa, Mototsugu
Hashinokuchi, Asato
Nagano, Taichi
Kinoshita, Fumihiko
Akamine, Takaki
Kohno, Mikihiro
Toyokawa, Gouji
Yoshizumi, Tomoharu
TRANSPLANT INTERNATIONAL, 2024, 37
[25] Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer
Shi, Bin
Behrens, Carmen
Vaghani, Viralkumar
Riquelme, Erick Marcelo
Rodriguez-Canales, Jaime
Kadara, Humam
Lin, Heather
Lee, Jack
Liu, Hui
Wistuba, Ignacio
Simon, George
CANCER MEDICINE, 2019, 8 (14): : 6383 - 6392
[26] Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma
Nakagawa, Shigeki
Okabe, Hirohisa
Ouchi, Mayuko
Tokunaga, Ryuma
Umezaki, Naoki
Higashi, Takaaki
Kaida, Takatoshi
Arima, Kota
Kitano, Yuki
Kuroki, Hideyuki
Mima, Kosuke
Nitta, Hidetoshi
Imai, Katsunori
Hashimoto, Daisuke
Yamashita, Yo-ichi
Chikamoto, Akira
Baba, Hideo
HPB, 2018, 20 (10) : 939 - 948
[27] Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis
Au, Sandy Leung-Kuen
Wong, Carmen Chak-Lui
Lee, Joyce Man-Fong
Fan, Dorothy Ngo-Yin
Tsang, Felice Hoching
Ng, Irene Oi-Lin
Wong, Chun-Ming
HEPATOLOGY, 2012, 56 (02) : 622 - 631
[28] Targeting enhancer of zeste homolog 2 protects against acute kidney injury
Zhou, X.
Zang, X.
Guan, Y.
Tolbert, T.
Zhao, T. C.
Bayliss, G.
Zhuang, S.
CELL DEATH & DISEASE, 2018, 9
[29] CLINICAL VALUE OF ENHANCER OF ZESTE HOMOLOG 2 AS A MARKER OF NEOPLASTIC PROGRESSION IN BREAST
Choi, J.
Oh, Y.
Kim, I.
Park, B.
Lee, Y.
ANNALS OF ONCOLOGY, 2008, 19 : 58 - 58
[30] Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases
Mimori, K
Ogawa, K
Okamoto, M
Sudo, T
Inoue, H
Mori, M
EJSO, 2005, 31 (04): : 376 - 380

← 1 2 3 4 5 →